Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus MEDROXYPROGESTERONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus MEDROXYPROGESTERONE ACETATE.
AMEN vs MEDROXYPROGESTERONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Medroxyprogesterone acetate is a progestin that binds to progesterone receptors, inhibiting gonadotropin secretion (LH, FSH) from the pituitary, thereby suppressing ovulation and altering the endometrial lining.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
150 mg IM every 3 months for contraception; 400-1000 mg IM weekly for endometrial cancer; 5-10 mg PO daily for secondary amenorrhea.
None Documented
None Documented
Clinical Note
moderateMedroxyprogesterone acetate + Digoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Digitoxin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMedroxyprogesterone acetate + Deslanoside
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMedroxyprogesterone acetate + Acetyldigitoxin
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life is approximately 12-17 hours after oral administration; with depot intramuscular injection, the half-life is prolonged (up to 50-60 days due to slow release from injection site).
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Primarily metabolized in the liver; metabolites are excreted in urine (50-70%) and feces (30-50%). Less than 5% excreted unchanged in urine.
Category C
Category D/X
Progestin
Progestin
"Medroxyprogesterone acetate may decrease the cardiotoxic activities of Acetyldigitoxin."